Insider · CIK 0001381994
Dennis A Ausiello
director
Files at ALNY (ALNYLAM PHARMACEUTICALS, INC.), MCRB (Seres Therapeutics, Inc.), RANI (Rani Therapeutics Holdings, Inc.). First filing Aug 15, 2025, latest Aug 15, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $14M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ALNY: ALNYLAM PHARMACEUTICALS, INC.
ALNYOct 9, 2026 · close 232.68
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | $14M 31,448 shares | -97% | +97% from low0% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +9,000 | $72.01 | $648k | 9,911 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +5,153 | $128.31 | $661k | 15,064 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +4,581 | $148.77 | $682k | 19,645 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +5,228 | $151.22 | $791k | 24,873 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +4,032 | $171.95 | $693k | 28,905 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +3,454 | $189.87 | $656k | 32,359 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,985 | $430.81 | $855k | 30,374 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,938 | $432.94 | $839k | 28,436 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -2,098 | $434.50 | $912k | 26,338 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -7,675 | $435.40 | $3.3M | 18,663 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -5,358 | $436.00 | $2.3M | 13,305 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,922 | $437.56 | $841k | 11,383 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -2,086 | $438.34 | $914k | 9,297 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -5,302 | $439.27 | $2.3M | 3,995 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,238 | $440.54 | $545k | 2,757 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,205 | $441.88 | $532k | 1,552 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -641 | $442.66 | $284k | 911 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -9,000 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,153 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,581 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,228 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,032 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,454 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Jul 1, 2025 | MCRB Seres Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +6,452 | $0.00 | $0 | 6,452 | Jul 2, 2025 |
| May 28, 2025 | RANI Rani Therapeutics Holdings, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 30, 2025 |
| May 8, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | AGrant or award Common Stock | +775 | $0.00 | $0 | 911 | May 12, 2025 |
| May 8, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +1,558 | $0.00 | $0 | 1,558 | May 12, 2025 |
| Apr 10, 2025 | MCRB Seres Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 11, 2025 |
| Dec 16, 2024 | RANI Rani Therapeutics Holdings, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -101,276 | - | - | 0 | Dec 17, 2024 |
| Dec 16, 2024 | RANI Rani Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +101,276 | - | - | 101,276 | Dec 17, 2024 |
| Dec 16, 2024 | RANI Rani Therapeutics Holdings, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,423 | - | - | 0 | Dec 17, 2024 |
| Dec 16, 2024 | RANI Rani Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +15,423 | - | - | 79,317 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.